Skip to content
MarketScale
‹ Back to IndustriesSciences

Bill Gates-Led Fund Backs Startup With Cheaper Way to Move Hydrogen

(Bloomberg) — A hydrogen molecule is tiny. So tiny, in fact, that trying to store and transport it via existing tanks and pipes can end up causing cracks in steel. If hydrogen is to become a clean fuel of the future, urgent technological solutions are needed to keep it in place and move it at…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share
Bill Gates-Led Fund Backs Startup With Cheaper Way to Move Hydrogen

Key takeaways

01

(Bloomberg) — A hydrogen molecule is tiny.

02

So tiny, in fact, that trying to store and transport it via existing tanks and pipes can end up causing cracks in steel.

03

If hydrogen is to become a clean fuel of the future, urgent technological solutions are needed to keep it in place and move it at…

(Bloomberg) —

A hydrogen molecule is tiny. So tiny, in fact, that trying to store and transport it via existing tanks and pipes can end up causing cracks in steel. If hydrogen is to become a clean fuel of the future, urgent technological solutions are needed to keep it in place and move it at will.

Enter H2SITE, a Spanish startup, that promises to do just that. It’s secured 12.5 million euros ($13.23 million) in investments from Bill Gates-led Breakthrough Energy Ventures, French utility Engie SA and Norwegian oil giant Equinor ASA.

While there are existing methods to store and transport hydrogen, they can be prohibitively expensive, especially compared to moving around its carbonaceous cousin natural gas. H2SITE says that transporting hydrogen could cost as much as three times the cost of hydrogen production. The startup offers to provide that service at a fraction of a cost, if its technology can scale.

There are two modes in which H2SITE’s technology works. First is to use existing natural-gas pipelines to move hydrogen from where it’s produced to where it is consumed. These pipes can carry about 30% hydrogen when mixed with natural gas. The idea is that diluted hydrogen will be less corrosive on existing steel infrastructure. Freshly produced hydrogen is injected into a pipeline containing natural gas, close to where hydrogen is made, and then recovered using H2SITE’s filter where it needs to be consumed.

“It’s like being able to separate a great Bordeaux wine after it’s mixed with a common wine,” said Sebastien Arbola, executive vice president at Engie.

No sieve in the world can filter out hydrogen (or separate a Bordeaux from supermarket wine). So H2SITE makes use of some clever chemistry that exploits hydrogen’s liking for certain metals such as palladium. Under the right conditions of heat and pressure, a hydrogen atom on the surface of a palladium alloy can split apart and reform when the temperature and pressure are lower. That means H2SITE can filter hydrogen at 99.9% purity from a pipe carrying between 5% and 30% hydrogen with the rest being natural gas.

That’s not all. If it’s not pipes, hydrogen (H₂) is likely to be moved around in ships — not as itself but trapped within ammonia (NH₃) or methanol (CH₃OH). That’s because ammonia can be easily turned into a liquid and methanol is already a liquid. There are currently projects being developed in countries like Australia that have plenty of space for solar and wind farms where hydrogen is produced, converted to ammonia, moved on ships, and then hydrogen is recovered by undoing the chemical reaction.

Obviously, the process of converting hydrogen to ammonia and back is highly energy intensive. Bringing down the cost of ammonia cracking will be key to making large investments to scale up hydrogen production for exports, according to Anja-Isabel Dotzenrath, executive vice president of gas and low carbon energy at BP Plc. “What we need to address is the cost of ammonia cracking,” Dotzenrath said in a recent interview about the company’s plans for a green hydrogen hub in Australia.

H2SITE’s second mode of operation causes it to become a cracker for ammonia or methanol. All that needs to be done, according to Andrés Galnares, H2SITE’s chief executive officer, is to increase the number of palladium membranes and tweak the temperature and pressure at which the reactor is run.

“It is early days” for H2SITE, said Arbola. The startup has reactors that can be used to filter out 40 kilograms of hydrogen per day, whereas its commercial units will be able to handle 200kg and 500kg respectively. Once scaled up, Galnares says that the cost of filtering the clean-burning fuel will be about $0.80 per kilogram of hydrogen.

The startup already has three sites where the technology will be tested. In the UK, ammonia made with renewable hydrogen will be converted to hydrogen. In Spain, a consortium of energy companies and research centers will test the generation, injection and transportation of hydrogen, with H2SITE providing reactors for filtering. In France, H2SITE’s reactors will generate hydrogen for vehicles.

Engie’s Arbola is clear that in building out hydrogen infrastructure or repurposing existing pipelines, it’s important to ensure that hydrogen doesn’t leak. That’s because, while hydrogen isn’t a greenhouse gas, it can extend the life of existing potent warming gases like methane or cause the production of another greenhouse gas ozone.

With natural gas prices at such highs, clean energy research group BloombergNEF finds that green hydrogen is now cheaper than natural gas in eight European countries. That means you can expect more startups with technologies that work to make the hydrogen economy a reality.

–With assistance from Will Mathis.

To contact the author of this story:

Akshat Rathi in London at arathi39@bloomberg.net

More stories like this are available on bloomberg.com

© 2022 Bloomberg L.P.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences